Atria Investments LLC Cellectis S.A. Transaction History

Atria Investments LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	BUY	$7.81 - $18.82 $40,151 - $96,753	5,141 Added 28.79%	22,998 $212,000
Q4 2019 Feb 11, 2020	BUY	$9.73 - $19.31 $173,748 - $344,818	17,857 New	17,857 $306,000
Q3 2019 Nov 14, 2019	SELL	$10.15 - $16.89 $142,993 - $237,946	-14,088 Closed	0 $0
Q2 2019 Aug 26, 2019	BUY	$14.6 - $20.6 $205,684 - $290,212	14,088 New	14,088 $181,000
Q2 2019 Aug 09, 2019	SELL	$14.6 - $20.6 $216,678 - $305,724	-14,841 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$15.53 - $19.75 $55,069 - $70,033	3,546 Added 31.39%	14,841 $272,000
Q4 2018 Feb 12, 2019	BUY	$15.58 - $28.41 $175,976 - $320,890	11,295 New	11,295 $188,000

11.2M

2.8K

17.9K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $82.8M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Atria Investments LLC, based on Form 13F filings with the SEC.

Stay updated on Atria Investments LLC with notifications on news.